For patients who develop diabetes after pancreatic cancer surgery, glucose management is among the most dangerous and demanding clinical challenges in oncology aftercare. Unlike type 1 or type 2 diabetes, post-pancreatectomy diabetes — formally classified as type 3c — strips away the hormonal redundancies that buffer against life-threatening blood sugar swings, leaving patients acutely vulnerable to severe hypoglycemia with little physiological warning. The question of whether automated insulin delivery technology can meaningfully close that gap has lacked rigorous evidence — until now.
This PRISMA-compliant systematic review, prospectively registered on PROSPERO and assessed using GRADE methodology, identified four qualifying studies — three randomized trials and one prospective time-motion simulation — enrolling a total of 66 adults with diabetes secondary to pancreatic resection for malignancy. The headline finding is stark: fully closed-loop insulin delivery systems raised time-in-range to 77.7% compared with just 41.1% under standard care, while virtually eliminating severe hypoglycemia events. A bihormonal artificial pancreas — combining insulin and glucagon — pushed euglycemia from 54% to 78% and reduced time below range to zero. A hybrid closed-loop system sustained glycemic improvements across longer follow-up, and a simulation model estimated a 67% reduction in nursing workload burden attributable to glucose monitoring and correction tasks.
The limitations here are substantial and must temper enthusiasm. The total cohort of 66 participants across four studies represents an extremely thin evidence base, and the mechanistic heterogeneity between fully closed-loop, bihormonal, and hybrid systems complicates direct comparison. Post-pancreatectomy diabetes remains an understudied niche relative to its clinical burden, and randomized trial infrastructure for this population is genuinely difficult to build given the oncologic context. That said, the magnitude of improvement in time-in-range — nearly doubling against standard care — is clinically meaningful by any benchmark. For health-conscious adults navigating cancer survivorship or supporting affected family members, this review signals that automated glucose technologies developed for type 1 diabetes may translate powerfully to a population that arguably needs them more urgently. The finding warrants larger, adequately powered trials before this technology becomes standard of care, but the directional signal is unusually clean for a sparse evidence base.